Nav: Home

Sanyal Biotechnology LLC announces strategic partnership with OWL Metabolomics, S.L.

April 17, 2016

April 16, 2016 - Richmond, Virginia and Barcelona, Spain: Sanyal Biotechnology LLC and One Way Liver S.L. (OWL Metabolomics) have initiated a strategic partnership to provide increased value and additional R&D services to basic research and the pharmaceutical industry, announced at the International Liver Congress in Barcelona, Spain.

Research companies and institutions who utilize Sanyal Biotechnology's full service preclinical drug screening services on the proprietary DIAMONDtm mouse model can now include advanced lipidomic profiling analysis on tissues such as the liver. Sanyal Biotechnology is engaged with OWL because of their excellent industry reputation for providing high-quality scientific data on the metabolomic profile of tissue and fluid samples. This partnership will result in an increase in the depth and quality of scientific data available to CRO's and pharmaceutical companies during their drug development process.

Rebecca Caffrey, CEO of Sanyal Biotechnology, said: "We are very excited by the great potential of this collaboration. Our DIAMONDtm mice are in great demand by pharmaceutical companies who are developing drugs to treat various aspects of the metabolic syndrome, particularly dyslipidemia and liver diseases such as NAFLD and NASH. Because the changes in lipid profiles of our model closely parallel those seen in the progression of human disease, our clients want to know how their drugs change the lipid profiles of the DIAMONDtm mice during the course of studies. By partnering with OWL, we are able to offer researchers excellent and accurate analyses that will enhance their preclinical drug development."

OWL's CEO, Pablo Ortiz, MD, PhD, added: "OWL Metabolomics and our team of liver research professionals are extremely excited to be involved in such an important partnership with Sanyal Biotechnology. Newly-developed drugs are becoming more targeted and personalized for many diseases, while regulatory authorities increasingly seek more specific technologies in evaluating early-stage drug candidates and determining the most appropriate patient selection for a given drug. We fully anticipate that our novel metabolomics-based testing will serve as a robust surrogate marker for specific histopathological changes in target organs"
About Sanyal Biotechnology

Sanyal Biotechnology is a contract research organization focused on accelerating the search for a cure for NASH. The company has proprietary technology, the DIAMONDtm mouse, which is a superior mouse model for the development of liver diseases that accompany the obesity and Type 2 diabetes epidemics. Sanyal Biotechnology's preclinical drug screening services enable pharmaceutical companies to identify the compounds which are most likely to succeed in human clinical trials, thus shortening the timeline to drug approval.

Sanyal Biotechnology LLC is a privately held company based in Richmond, Virginia. The company was spun out of Virginia Commonwealth University in 2015.

For more information:

About OWL Metabolomics

OWL Metabolomics is a biotechnology company committed to the identification, validation and global commercialization of diagnostic assays for the liver and other prevalent human diseases, including the identification of potential therapeutic targets involved in the development of such diseases. Since its inception in 2002, OWL has pioneered novel diagnostic research within the fatty liver space.

The 'OWL Liver' and 'OWL Liver Care' assays are the world's first metabolomics-based in-vitro tests for diagnosing NASH and hepatic steatosis (NAFLD), respectively, using micro-blood samples ( <0.5 ml) versus today's diagnostic gold-standard which mandates an invasive liver biopsy.

OWL Metabolomics is a privately-held company based in Derio, Spain and collaborates globally with hospitals, liver research centers, biotechnology groups and the pharmaceutical industry.

More information -

Contact: Sanyal Bio Investor Relations:
Rebecca Caffrey/ Steve Carroll
Chief Executive Officer CFO
US 804-594-6863 US 804-594-6863

European Association for the Study of the Liver

Related Diseases Articles:

Using gene scissors to detect diseases
Researchers present sensor prototype that can rapidly, precisely, and cost-effectively measure molecular signals for cancer.
Ants fight plant diseases
New research from Aarhus University shows that ants inhibit at least 14 different plant diseases.
New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.
Cascade exacerbates storage diseases
In rare, hereditary storage diseases such as Sandhoff's disease or Tay-Sachs syndrome, the metabolic waste from accumulating gangliosides cannot be properly disposed of in the nerve cells because important enzymes are missing.
What is known -- and not known -- about heart muscle diseases in children
Cardiomyopathies (heart muscle diseases) in children are the focus of a new scientific statement from the American Heart Association that provides insight into the diagnosis and treatment of the diseases as well as identifying future research priorities.
Autoimmune diseases are related to each other, some more than others
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.
Skin diseases are more common than we think
Skin diseases are ranked as the fourth most common cause of human illness, but many affected people do not consult a physician.
Across diseases, women are diagnosed later than men
When considering all diseases, there are big differences between the course of men's and women's patient care within the Danish healthcare system.
The Lancet Infectious Diseases: Experts warn of a surge in vector-borne diseases as humanitarian crisis in Venezuela worsens
The ongoing humanitarian crisis in Venezuela is accelerating the re-emergence of vector-borne diseases such as malaria, Chagas disease, dengue, and Zika virus, and threatens to jeopardize public health gains in the country over the past two decades, warn leading public health experts.
New mutation in amyloid diseases discovered
Researchers have identified a one-of-a kind mutation in the DNA of a patient who died of transthyretin (TTR) amyloidosis, a progressive condition characterized by the buildup of abnormal deposits of a misfolded protein called amyloid in the body's organs and tissues.
More Diseases News and Diseases Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Accessing Better Health
Essential health care is a right, not a privilege ... or is it? This hour, TED speakers explore how we can give everyone access to a healthier way of life, despite who you are or where you live. Guests include physician Raj Panjabi, former NYC health commissioner Mary Bassett, researcher Michael Hendryx, and neuroscientist Rachel Wurzman.
Now Playing: Science for the People

#544 Prosperity Without Growth
The societies we live in are organised around growth, objects, and driving forward a constantly expanding economy as benchmarks of success and prosperity. But this growing consumption at all costs is at odds with our understanding of what our planet can support. How do we lower the environmental impact of economic activity? How do we redefine success and prosperity separate from GDP, which politicians and governments have focused on for decades? We speak with ecological economist Tim Jackson, Professor of Sustainable Development at the University of Surrey, Director of the Centre for the Understanding of Sustainable Propserity, and author of...
Now Playing: Radiolab

An Announcement from Radiolab